215 related articles for article (PubMed ID: 23462153)
1. Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis.
Jenkins G
Thorax; 2013 Jul; 68(7):603-5. PubMed ID: 23462153
[No Abstract] [Full Text] [Related]
2. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V; Ravaglia C; Tomassetti S
Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
[TBL] [Abstract][Full Text] [Related]
3. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
4. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
Potts J; Yogaratnam D
Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
[TBL] [Abstract][Full Text] [Related]
5. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
Kingwell K
Nat Rev Drug Discov; 2014 Jul; 13(7):483-4. PubMed ID: 24981347
[No Abstract] [Full Text] [Related]
6. FDA panel likes new treatment for idiopathic pulmonary fibrosis.
Morrow T
Manag Care; 2010 Apr; 19(4):53-4. PubMed ID: 20446566
[No Abstract] [Full Text] [Related]
7. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
Selvaggio AS; Noble PW
Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic pulmonary fibrosis and pirfenidone.
Collard HR
Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
[No Abstract] [Full Text] [Related]
10. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Xaubet A; Serrano-Mollar A; Ancochea J
Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
[TBL] [Abstract][Full Text] [Related]
11. Is pirfenidone effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].
Tokura T; Oku H; Tsukamoto Y
Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):97-104. PubMed ID: 19672005
[No Abstract] [Full Text] [Related]
13. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
[No Abstract] [Full Text] [Related]
14. Two new drugs for idiopathic pulmonary fibrosis.
Med Lett Drugs Ther; 2014; 56(1457):123-4. PubMed ID: 25461229
[No Abstract] [Full Text] [Related]
15. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
Hilberg O; Simonsen U; du Bois R; Bendstrup E
Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone for IPF: pro/con debate; the 'con' viewpoint.
Raghu G; Thickett DR
Thorax; 2013 Jul; 68(7):605-8. PubMed ID: 23462155
[No Abstract] [Full Text] [Related]
17. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Moodley Y; Corte T; Richeldi L; King TE
Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
[TBL] [Abstract][Full Text] [Related]
18. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
King CS; Nathan SD
Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
[No Abstract] [Full Text] [Related]
19. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
Brown KK
Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
[No Abstract] [Full Text] [Related]
20. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
Raghu G; Selman M
Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
